Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 11/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | JAK1 | P23458 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | MAP3K12 | Q12852 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10070234 | 0.92 | MTOR (0.44) | MTORPIK3CAJAK2JAK1JAK3 | |
| SCHEMBL808108 | 0.90 | MTOR (0.48) | MTORPIK3CAMAP3K12 | |
| SCHEMBL808107 | 0.89 | PIK3CA (0.51) | MTORPIK3CAJAK2JAK1MAP3K12 | |
| SCHEMBL808274 | 0.86 | PIK3CA (0.44) | MTORPIK3CA | |
| SCHEMBL17243668 | 0.85 | MAP3K12 (0.47) | MTORPIK3CAJAK1MAP3K12 | |
| SCHEMBL15123601 | 0.85 | PIK3CA (0.46) | MTORPIK3CA | |
| SCHEMBL10069679 | 0.85 | MAP3K12 (0.46) | MTORPIK3CAMAP3K12 | |
| SCHEMBL808101 | 0.85 | MTOR (0.44) | MTORPIK3CAMAP3K12 | |
| SCHEMBL10070216 | 0.85 | RAF1 (0.45) | MTORPIK3CAJAK1JAK3MAP3K12 | |
| SCHEMBL808273 | 0.85 | MTOR (0.53) | MTORPIK3CAJAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181264-B2 | Fused heteroaryls and their uses | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-11-10 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-07-25 | — | — | US | disclosed |
| WO-2012034526-A1 | FUSED HETEROARYLS AND THEIR USES | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190307-A1 | FUSED HETEROARYLS AND THEIR USES | FARS2, TIAL1, DHFR | MTOR 4193/4885PIK3CA 1962/4885JAK2 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.